DC4 Crosslinker

Confirm delete?

DC4 Crosslinker

Zoom

Cat No: 14734

Biochemicals - Peptides

DC4 crosslinker is a mass spectrometry-cleavable crosslinking reagent (18Å in length) that contains two intrinsic positive charges, which allow cross-linked peptides to fragment into their component peptides by collision-induced dissociation or in-sou...

This product can only be bought through Cayman Chemical. Please contact us.

Product Overview
Data
Downloads
About Cayman

Territorial Availability: Available through Bertin Technologies only in France

Synonyms:

1,4-bis[4-[(2,5-dioxo-1-pyrrolidinyl)oxy]-4-oxobutyl]-1,4-diazoniabicyclo[2.2.2]octane, dibromide

Correlated keywords:

1374743-69-7 crosslinkers crosslinking cross links linking linked cross-linked cross-linking cross-linked proteinsprotein-protein interactions mass spectrometry MS collision-induced collisions induced dissociation CIDs in-source decay ISDs mapping maps DC-4 DCs four 4 pairs ions masses fragments b- y- b y

Product Overview:
DC4 crosslinker is a mass spectrometry-cleavable crosslinking reagent (18Å in length) that contains two intrinsic positive charges, which allow cross-linked peptides to fragment into their component peptides by collision-induced dissociation or in-source decay.{23356} Initial fragmentation events result in cleavage on either side of the positive charges so that cross-linked peptides can be identified as pairs of ions separated by defined masses.{23356} Additionally, these two intact peptide fragments can be further fragmented to yield a series of b- and y-ions for peptide identification.{23356}

Size	5 mg
Shipping	dry ice
CAS Number	1374647-94-5
Molecular Formula	C₂₂H₃₂N₄O₈ • 2Br
SMILES	O=C(ON1C(CCC1=O)=O)CCC[N+]23CC[N+](CC3)(CCCC(ON4C(CCC4=O)=O)=O)CC2.[Br-].[Br-]
Molecular Weight	640,3
Formulation	A crystalline solid
Purity	≥98%
Custom Code	2932.99
UNSPSC code	12352100

Technical File

MSDS

Click here to ask for your quote and get 15% off Cayman's products.

Cayman Chemical's mission is to help make research possible by supplying scientists worldwide with the basic research tools necessary for advancing human and animal health. Our utmost commitment to healthcare researchers is to offer the highest quality products with an affordable pricing policy.

Our scientists are experts in the synthesis, purification, and characterization of biochemicals ranging from small drug-like heterocycles to complex biolipids, fatty acids, and many others. We are also highly skilled in all aspects of assay and antibody development, protein expression, crystallization, and structure determination.

Over the past thirty years, Cayman developed a deep knowledge base in lipid biochemistry, including research involving the arachidonic acid cascade, inositol phosphates, and cannabinoids. This knowledge enabled the production of reagents of exceptional quality for cancer, oxidative injury, epigenetics, neuroscience, inflammation, metabolism, and many additional lines of research.

Our organic and analytical chemists specialize in the rapid development of manufacturing processes and analytical methods to carry out clinical and commercial GMP-API production. Pre-clinical drug discovery efforts are currently underway in the areas of bone restoration and repair, muscular dystrophy, oncology, and inflammation. A separate group of Ph.D.-level scientists are dedicated to offering Hit-to-Lead Discovery and Profiling Services for epigenetic targets. Our knowledgeable chemists can be contracted to perform complete sample analysis for analytes measured by the majority of our assays. We also offer a wide range of analytical services using LC-MS/MS, HPLC, GC, and many other techniques.

Accreditations
ISO/IEC 17025:2005
ISO Guide 34:2009

Cayman is a leader in the field of emerging drugs of abuse, providing high-purity Schedule I-V Controlled Substances to federally-licensed laboratories and qualified academic research institutions for forensic analyses. We are certified by ACLASS Accreditation Services with dual accreditation to ISO/IEC 17025:2005 and ISO Guide 34:2009.